Another partial NTD-dependent compound, radotinib,is a C-abl kinase inhibitor  an MOA that is being pursuedfor ALS and is currently being explored as a potential Parkinson’sdisease therapeutic., These results suggest that broadeningthe counter-screen criterion to include partial NTD-dependent moleculesmay enrich for additional compounds with activity toward TDP-43. Here, TARDBP is linked to amyotrophic lateral sclerosis.